無錫新利体育18制藥有限公司，前身為無錫市第二制藥廠，為江蘇省高新技術企業和江蘇省科技創新型企業, 始建于1943年，位于風景秀美的太湖之濱。公司注冊資本32000萬元人民幣，占地面積100,000平方米。公司主要生產抗生素原料藥、化學合成原料藥以及口服固體制劑；發酵總量近500立方米，建有8個符合國內國際GMP要求的生產車間。
無錫新利体育18制藥有限公司秉承“祈康厚生，福澤民眾”的信念宗旨，致力于原料藥和成品藥研發和生產，為客戶提供更好的產品與服務。公司質量管理體系完善，設備儀器先進，產品質量優良，配套設施完善。公司通過了由國內外藥品監督管理機關組織中囯GMP（2010）及歐洲GMP認證，通過了清潔生產審核以及中經科環基于GB/T24001-2016 idt ISO14001：2015 標準的環境管理體系認證；GB/T45001-2020 idt ISO45001：2018 標準的職業健康安全管理體系認證。
公司擁有一大批高技術專業人士組成的人才隊伍，從事著管理、科研、開發、生產、營銷工作。
企業目前主要產品有硫酸奈替米星，硫酸西索米星，硫酸核糖霉素及螺旋霉素等抗生素藥物，嗎替麥考酚酯，他克莫司等器官移植抗排斥方面的藥物，產品遠銷歐洲，美洲，非洲，及東南亞等幾十個國家和地區。得天獨厚的先天優勢，造就了企業深厚的文化底蘊；雄厚的科學技術力量，為企業的長足發展創造了機遇。在以質量求生存，以創新謀發展的經營理念的指導下，無錫新利体育18積極開發治療器官移植抗排斥藥，新型抗腫瘤藥以及保肝藥等一系列的新產品，并逐漸穩步拓展成品藥市場，為企業中長期的發展提供持久動力。
強大的研發實力，堅實的生產技術，先進的管理理念，創新的經營思路和不斷自我提升的質量管理體系是無錫新利体育18的競爭優勢，企業正努力把自身建設成為國內外知名的現代化制藥企業。
WuxiFortune Pharmaceutical co., LTD is formerly known as Wuxi No. 2 Pharmaceutical Factory, is an new high-tech enterprise and technological innovation-based enterprise in Jiangsu Province. It was established in 1943 and located nearby the beautiful Taihu Lake. The registered capital is 320,000,000 RMB, and the total area is 100,000 m2. The main products are antibiotic APIs, chemical synthesis APIs and oral solid preparations. The total fermentation amount is about 500m3. There are eight workshops complied with the requirements of Current Chinese GMP (2010 version), which is equal to that of EU GMP, WHO GMP and ICH Q7A.
Wuxi Fortune pharmaceutical Co., LTD., adheres to the belief of "pray for the health, improve the living condition, bless the people", devotes to developing and manufacturing API and finished products, and provide better products and services. We have complete quality assurance system, advanced facility, providing good products, and perfect matching facilities. The company has passed the Chinese GMP (2010) Certification and European GMP Certification conducted by domestic and foreign regulatory administration authorities, cleaning production audit, the Environmental Management System Certification (GB/T24001-2016/ISO ISO14001:2015), and the Occupational Health and Safety Management System Certification (GB/T45001-2020/ISO 45001:2018) conducted by Beijing Zhongjing Quality Certification Co., Ltd.
At present, the main products are antibiotics drugs such as Netilmicin Sulfate, Sisomicin Sulfate, Ribostamycin Sulfate, and Spiramycin etc. and immunosuppressant like Mycophenolate Mofetiland Tacrolimus. Most of our products are exported to Europe, America, Africa, and Southeast Asia.
The advantagedsuperiority creates deep enterprise culture and the abundant science and technology strength create the development opportunities. Now Wuxi Fortune develops on the organ transplantation anti-rejection drugs, new antineoplastic and hepatoprotective. We also gradually expand the market of finished drug products to provide enduring power for the enterprise development. Strong research and development strength, firm production technology, advanced management ideas, innovative business ideas and continuous self-improvement quality management system are our competitive advantage. We work hard to make the enterprise become a famous modern pharmaceutical enterprise.
